Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)

Soto, Alvaro Juarez

Gomes, Andrea Juliana Pereira de Santana

Given, Robert W.

Merseburger, Axel Stuart

Ozguroglu, Mustafa

Uemura, Hirotsugu

Ye, Dingwei

Londhe, Anil

Lopez-Gitlitz, Angela

McCarthy, Sharon Anne

Mundle, Suneel

Chi, Kim N.

Agarwal, Neeraj

Chowdhury, Simon

Bjartell, Anders

Chung, Byung Ha